Lance Berger, MD
Cardiovascular Disease · Toms River, NJNPI 1689679490
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Pfizer at 51.7% of the total. Reporting peaked in 2024 at $5,864 and has fallen 84.5% since, to $910 in 2025.
Across 162 payments — averaging $73.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$6K
- Abbott$1K
- Novartis$1K
- AstraZeneca$748
- E.r. Squibb & Sons, L.L.C.$705
- Boston Scientific$464
- plus $1K from 23 others
Across 13 payments — averaging $9238.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$120K
What the payments were for
- Consulting fees$1,18810%
- Speaking & faculty fees$4,60039%
- Travel & lodging$1,99217%
- Food & beverage$4,09034%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 31 | $6,146 |
| Abbott | 13 | $1,394 |
| Novartis | 10 | $1,325 |
| AstraZeneca | 15 | $748 |
| E.r. Squibb & Sons, L.L.C. | 28 | $705 |
| Boston Scientific | 10 | $464 |
| Alnylam Pharmaceuticals Inc. | 16 | $287 |
| Daiichi Sankyo Inc. | 2 | $129 |
| Johnson & Johnson | 7 | $106 |
| Irhythm Technologies, Inc. | 3 | $100 |
| Biosense Webster, Inc. | 2 | $71 |
| Heartflow, Inc. | 2 | $48 |
| Portola Pharmaceuticals, LLC | 3 | $42 |
| Boehringer Ingelheim | 2 | $32 |
| Amgen | 2 | $30 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $29 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Livanova USA, Inc. | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Cleerly, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Philips North America LLC | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Bridgebio Pharma, Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Acarix USA Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$5,810
- Mitra Clip system$1,250
- LEQVIO$1,188
- WAINUA$362
- CAMZYOS$251
- FARXIGA$234
- RESONATE$226
- AMVUTTRA$121
- INJECTAFER$120
- Watchman$100
How this compares
$11,888 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 15 | $487,898 |
| EliquisApixaban | 238 | $279,010 |
| EntrestoSacubitril/Valsartan | 95 | $113,408 |
| XareltoRivaroxaban | 54 | $59,980 |
| FarxigaDapagliflozin Propanediol | 68 | $56,007 |
| Repatha SureclickEvolocumab | 47 | $47,456 |
| BrilintaTicagrelor | 18 | $19,829 |
| JardianceEmpagliflozin | 15 | $10,233 |
| Icosapent Ethyl | 15 | $8,613 |
| Rosuvastatin Calcium | 385 | $6,336 |
| Carvedilol ErCarvedilol Phosphate | 12 | $6,076 |
| Ezetimibe | 216 | $5,675 |
| Atorvastatin Calcium | 393 | $4,425 |
| Metoprolol Succinate | 245 | $4,300 |
| Valsartan | 55 | $2,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $6,146 | $766,908253 claims |
| NovartisEntresto | $1,325 | $113,40895 claims |
| AstraZenecaFarxiga, Brilinta | $748 | $75,83686 claims |
| Johnson & JohnsonXarelto | $106 | $59,98054 claims |
| Boehringer IngelheimJardiance | $32 | $10,23315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Toms River
- Hani DouediToms River$72K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.